Abstract:Transposons have emerged as promising vectors for gene therapy that can potentially overcome some of the limitations of commonly used viral vectors. Transposons stably integrate into the target cell genome, enabling persistent expression of therapeutic genes. Transposons have evolved from being used as basic tools in biomedical research to bona fide therapeutics. Currently, the most promising transposons for gene therapy applications are derived from Sleeping Beauty (SB) or piggyBac (PB). Stable transposition requires co-delivery of the transposon DNA with the corresponding transposase gene, mRNA, or protein. Stable transposition efficiency can be substantially increased by using "next-generation" transposon systems that combine codon-usage optimization with hyper-activating mutations in the SB or PB transposases. By virtue of their relatively large capacity, gene therapy applications with relatively large therapeutic transgenes, such as full-length dystrophin, can now be envisaged. The authors and others have shown that efficient and stable gene transfer can be achieved with these next-generation transposons in several clinically relevant primary cells, such as CD34+ hematopoietic stem/progenitor cells, T cells, and mesenchymal and myogenic stem/progenitor cells that are amenable for ex vivo transfection. Alternatively, in vivo transposon gene delivery has been explored using non-viral vectors or nanoparticles or in combination with viral vectors. The therapeutic potential of these SB- and PB-based transposons has been demonstrated in preclinical models that mimic the cognate human diseases. However, there are still challenges impeding clinical translation of transposons pertaining mainly to the typical limiting efficiencies of most non-viral transfection methods and the intrinsic DNA toxicity. Nevertheless, it is particularly encouraging that transposons have now been used in gene therapy clinical trials. In particular, transposon-engineered T cells expressing chimeric antigen receptors are starting to yield promising results in patients with hematological malignancies.

Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy

Transposons: Moving Forward from Preclinical Studies to Clinical Trials

Recent developments in transposon-mediated gene therapy

Engineered Sleeping Beauty transposase redirects transposon integration away from genes

PiggyBac as a novel vector in cancer gene therapy: current perspective

DNA transposition by protein transduction of the piggyBac transposase from lentiviral Gag precursors

RNA-guided piggyBac transposition in human cells

Hyperactive Piggybac Gene Transfer in Human Cells and in Vivo

Piggybac Transposon Vectors: the Tools of the Human Gene Encoding

Unexpectedly High Copy Number of Random Integration but Low Frequency of Persistent Expression of the Sleeping Beauty Transposase after Trans Delivery in Primary Human T Cells.

Gene Transfer Efficiency and Genome-Wide Integration Profiling of Sleeping Beauty, Tol2, and PiggyBac Transposons in Human Primary T Cells

Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes

[The Improvement and Application of Piggybac Transposon System in Mammals].

An optimized polymeric delivery system for piggyBac transposition

Applications of Sleeping Beauty Transposons for Nonviral Gene Therapy

DNA binding and transposition activity of the Sleeping Beauty transposase: role of structural stability of the primary DNA-binding domain

Suicidal Autointegration of Sleeping Beauty and Piggybac Transposons in Eukaryotic Cells

Functional indications for transposase domestications - Characterization of the human piggyBac transposase derived (PGBD) activities

Sleeping Beauty Transposon Insertions into Nucleolar DNA by an Engineered Transposase Localized in the Nucleolus

Suicidal autointegration of sleeping beauty and piggyBac transposons in eukaryotic cells.

piggyBac as a high-capacity transgenesis and gene-therapy vector in human cells and mice.